Abivax SA (ABVX) Stock Forecast and Price Target (2026)

Last updated November 2026

Short answer

12 analysts covering Abivax SA (ABVX) carry an average price target of $163.58 as of November 2026, +95.6% against the $83.61 share price on November 16, 2026. The published targets run from $142.00 to $181.00, a spread of 24% of the average, so the disagreement is narrow. The rating split is 12 buy, 0 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market. Walnut is not an investment adviser.

ABVX analyst price targets

Price
$83.61
Average target
$163.58
Median target
$164.00
Implied vs price
+95.6%
Target range
$142.00 to $181.00
Analysts covering
12
Ratings
12 buy0 hold0 sell

ABVX analyst data as of November 2026, sourced from Yahoo Finance and may be delayed. The price is the last one Yahoo Finance reported on November 16, 2026.A price target is what an analyst published on a date, not a forecast Walnut endorses, and targets are typically set on a 12-month view. Verify current figures before deciding.

The average target of $163.58 sits well above the $83.61 price, +95.6%. The median is $164.00, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.

What the ABVX target range actually tells you

The published targets span $142.00 to $181.00. That gap is 24% of the average target, which counts as narrow disagreement. A spread that tight means the analysts broadly agree on the model, so the consensus is a reasonably stable read of a shared view.

The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the ABVX is it a buy page.

Recent analyst actions on ABVX

FirmActionTargetPriorDate
WedbushLowered (Neutral)$96.00$118.00October 21, 2026
GuggenheimMaintained (Buy)$175.00$175.00October 20, 2026
Truist SecuritiesLowered (Buy)$151.00$155.00September 22, 2026
WedbushLowered (Neutral)$118.00$140.00September 22, 2026
BarclaysMaintained (Overweight)$148.00$148.00September 22, 2026
Goldman SachsInitiated (Buy)$155.00-September 10, 2026
BTIGMaintained (Buy)$175.00$175.00September 5, 2026
Piper SandlerRaised (Overweight)$175.00$165.00July 9, 2026
Truist SecuritiesRaised (Buy)$155.00$135.00July 2, 2026
CitizensMaintained (Market Outperform)$187.00$187.00July 1, 2026
JefferiesRaised (Buy)$158.00$108.00June 30, 2026
Leerink PartnersRaised (Outperform)$148.00$140.00June 30, 2026

The most recent published rating actions on ABVX within the last six months, from Yahoo Finance. Each row is dated because a target only means something alongside the date it was set. Walnut is not an investment adviser and does not endorse any of these views.

In the last six months there have been 4 raises and 3 cuts among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.

How analysts rate ABVX

Of the analysts with a published rating, 12 say buy, 0 say hold, and 0 say sell, so 100% carry a buy. That mix has been broadly steady over the last three months.

The distribution says more than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.

Why a ABVX price target is not a prediction

  • It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
  • The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
  • Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
  • Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.

ABVX earnings and revenue forecast

For the fiscal year ending Dec 2026, the 14 analysts publishing estimates on ABVX expect earnings of -$4.17 per share and revenue of 4 million EUR (-13%).

PeriodEPS estimateEPS growthRevenue estimateRevenue growth
Quarter ending Sep 2026
next quarter to report, 6 analysts
-$0.86
-$1.11 to -$0.59
n/a676.4 thousand EUR
0 thousand EUR to 1.4 million EUR
-67%
Quarter ending Dec 2026
the quarter after, 6 analysts
-$0.89
-$1.16 to -$0.64
n/a686 thousand EUR
0 thousand EUR to 1.6 million EUR
+46%
Fiscal year ending Dec 2026
fiscal year next to report, 14 analysts
-$4.17
-$4.67 to -$3.81
n/a4 million EUR
0 thousand EUR to 8 million EUR
-13%
Fiscal year ending Dec 2027
the fiscal year after, 15 analysts
-$3.84
-$4.91 to -$2.52
n/a71.9 million EUR
0 thousand EUR to 374.7 million EUR
+1696%

Consensus estimates for ABVX published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Abivax SA next reports on September 21, 2026, which is when these figures get tested against actual results.

Is there a 2030 forecast for ABVX?

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering ABVX do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Abivax SA can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

What could move ABVX from here

In short: the drivers cited most often are Positive Phase 3 obefazimod data, Path to an FDA filing, Pipeline expansion into Crohn's disease. The risk cited most often against it is as a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the ABVX is it a buy page.

Your questions about Abivax SA

Ask Walnut's AI anything about ABVX and see how it fits what you own.

FAQ

What is the price target for Abivax SA (ABVX)?

+

The average analyst price target for ABVX is $163.58 as of November 2026, across 12 analysts. The average is +95.6% against the $83.61 share price on November 16, 2026, so the consensus sits well above where the stock trades. The median target, which is less distorted by one extreme view, is $164.00. Targets move constantly; verify the current figure before relying on it.

How high could ABVX go?

+

The highest published target is $181.00, which is +116.5% against the $83.61 price. It is one analyst's most optimistic case, not a ceiling and not a forecast. The lowest is $142.00. The gap between them answers this question best: analysts who all follow Abivax SA closely disagree by 24% of the average target, so treat any single number as one scenario.

How many analysts cover ABVX?

+

12 analysts publish estimates on ABVX as of November 2026. Of those with a published rating, 12 say buy, 0 hold, and 0 sell, so 100% carry a buy rating. More coverage usually means the consensus is better informed, though it also means the obvious points are already in the price.

Are analyst price targets for ABVX accurate?

+

Treat them as informed opinion, not measurement. Two things matter here. Sell-side ratings skew positive across the market, and ABVX is no exception at 100% buy ratings, so the distribution is not a balanced vote. And targets tend to follow the share price at least as often as they lead it, getting raised after a stock has already run. They are most useful as a read on what the informed consensus expects, and least useful as a prediction of where the price lands.

Has the ABVX price target been raised or cut recently?

+

In the last six months there have been 4 raises and 3 cuts among the published actions on ABVX. The most recent was Wedbush, which lowered its target to $96.00 from $118.00 on October 21, 2026. The direction of revisions often tells you more than the level, because it shows which way the informed view is moving.

What are analysts' earnings estimates for Abivax SA (ABVX)?

+

For the fiscal year ending Dec 2026, the 14 analysts publishing estimates on ABVX expect earnings of -$4.17 per share and revenue of 4 million EUR (-13%). For the fiscal year ending Dec 2027, the consensus is -$3.84 per share. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.

When does ABVX report earnings next?

+

Abivax SA's next earnings report is scheduled for September 21, 2026. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.

What is the ABVX stock price prediction for 2030?

+

There is no published one. Analyst targets run to about twelve months and no firm covering ABVX publishes a 2030 figure, so any site showing one has extrapolated a growth rate of its own. The answerable version of the question is what the current price already assumes about Abivax SA's earnings, which the forward multiple on this page sets out, and what would have to change for that to break.

Will ABVX go up in 2026?

+

Nobody knows, including the analysts publishing targets. What the numbers on this page tell you is where informed opinion currently sits and how much it disagrees with itself, which is useful and different from a prediction. The risk most often cited against Abivax SA: As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. Walnut is not an investment adviser.

Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.

Forecasts for similar stocks